Markets
← Back to Stocks
BIIB
BIOGEN INC
Health Care · Biotechnology
$183.40
+0.60%
Vol: 0.0M
Araverus Market Read
Thursday, March 19, 2026
Biogen gains traction on analyst support and upbeat guidance following Q4 beat
BIIB fell 0.67% in pre-market to $192.00 on March 19 with after-hours decline of 0.80% to $192.25 on March 18. H.C. Wainwright raised price target to $228 from $194, while HSBC raised target to $150 from $143 reflecting upbeat 2026 EPS outlook. Company beat Q4 earnings and sales expectations. Pre-market weakness reflects normal market volatility despite positive fundamental catalysts.
Price 50d 200d
Previous Market Reads
2 of 2 days↑
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$26.9B
P/E (TTM)20.9
Forward P/E11.3
Beta0.14
Div Yield—
Prev Close$182.31
RSI (14-Day)
40Neutral
0305070100
52-Week Range
$110.04$183.40$202.41
From High-9.4%
From Low+66.7%
Moving Averages
50d SMA
$184.42-0.6%
200d SMA
$156.62+17.1%
Price between 50d and 200d. Testing 50d support.
Returns
1W
-0.8%
1M
-5.5%
3M
+6.9%
6M
+26.6%
1Y
+28.2%
YTD
+3.1%
Volume
Today13K
20d Avg881K
Ratio0.01x